VR23 [Proteasome Inhibitor]

CHF 30.00
In stock
AG-CR1-3676-M0011 mgCHF 30.00
AG-CR1-3676-M0055 mgCHF 110.00
AG-CR1-3676-M02525 mgCHF 390.00
More Information
Product Details
Synonyms 7-Chloro-4-[4-[(2,4-dinitrophenyl)sulfonyl]-1-piperazinyl]quinoline
Product Type Chemical
Properties
Formula

C19H16ClN5O6S

MW 477.9
CAS 1624602-30-7
Purity Chemicals ≥98% (HPLC)
Appearance White solid.
Solubility Soluble in DMSO (10mg/ml) or DMF. Poorly soluble in aqueous solutions.
Identity Determined by 1H-NMR.
Other Product Data

Note: Warming and sonication may be required when dissolving the compound in the solvent of choice. Stock solutions are stable for at least 1 month when stored at -20°C.

InChi Key PDQVZPPIHADUOO-UHFFFAOYSA-N
Smiles O=S(N1CCN(C2=C(C=CC(Cl)=C3)C3=NC=C2)CC1)(C4=CC=C([N+]([O-])=O)C=C4[N+]([O-])=O)=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent selective and reversible chloroquine derivative 20S proteasome inhibitor (all proteolytic subunits).
  • Targets the trypsin-like β2 subunit of the constitutive 20S proteasome (IC50=1nM). Cross-reacts and inhibits the chymotrypsin-like β5 subunit (IC50=50-100nM) and the caspase-like/peptidyl-glutamyl peptide-hydrolyzing (PGPH) β1 subunit (IC50=3μM).
  • Anticancer compound effective in cell-based assays and against multiple myeloma and metastatic breast cancer in vivo.
  • In vitro, induces cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma, as well as in bortezomib-resistent multiple myeloma cells, but with minimal effects on non-cancerous cells.
Product References
  1. VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification: S. Pundir, et al.; Cancer Res. 75, 4164 (2015)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.